Actively Recruiting
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Led by Erasca, Inc. · Updated on 2025-09-11
200
Participants Needed
5
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
CONDITIONS
Official Title
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63 18 years
- Willing and able to give written informed consent
- Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts
- No available standard systemic therapy for the patient's tumor histology and/or molecular biomarker profile, or standard therapy is intolerable, not effective, not accessible, or refused
- Able to swallow oral medication
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- Adequate cardiovascular, hematological, liver, and renal function
- Willing to comply with all protocol-required visits, assessments, and procedures
You will not qualify if you...
- Previous treatment with a RAS inhibitor
- Currently receiving another study therapy or participated in an investigational agent study and received therapy within 4 weeks of first dose of ERAS-0015
- Received prior palliative radiation within 14 days of Cycle 1, Day 1
- Primary central nervous system (CNS) tumors
- Prior surgery (e.g., gastric bypass, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
- Any underlying medical, psychiatric condition, or social situation that would compromise study administration or assessment of adverse events
- Pregnant, breastfeeding, or expecting to conceive or father children during the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Florida Cancer Specalists
Sarasota, Florida, United States, 34232
Actively Recruiting
2
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
3
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
4
University of Texas at Tyler
Tyler, Texas, United States, 75701
Actively Recruiting
5
NEXT Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
E
Erasca Clinical Team Team
CONTACT
L
Les Brail, Study Director, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here